October 10, 2018 07:07 AM EDT

Novartis builds its case for a new sickle cell drug, eyeing a delayed FDA filing in ‘19

John Carroll

Editor & Founder

Researchers at Novartis have taken another crack at the data they collected in a Phase II study of their sickle cell disease drug crizanlizumab, building …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis builds its case for a new sickle cell drug, eyeing a delayed FDA filing in ‘19

John Carroll

Editor & Founder

Sign up to read this article for free.

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Biotech VC firm outlines plans for $100M fund

Gilead's Kite uncouples from Fosun in China as Yescarta faces coverage obstacles

Breaking down silos with a new quantitative approach to drug development

No­var­tis builds its case for a new sick­le cell drug, eye­ing a de­layed FDA fil­ing in ‘19

John Carroll

Editor & Founder

Sign up to read this article for free.

Sanofi's BTK in­hibitor again slows MS pro­gres­sion, but liv­er en­zymes con­tin­ue to be tricky

Lex­i­con's pres­i­dent to step down as de­ci­sion date looms; Sarep­ta wel­comes Lil­ly, GSK vet to board

No­vo says its CB1 drug helped shed weight, but ef­fi­ca­cy and safe­ty ques­tions re­main

Biotech VC firm out­lines plans for $100M fund

Gilead­'s Kite un­cou­ples from Fo­s­un in Chi­na as Yescar­ta faces cov­er­age ob­sta­cles

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

Novartis builds its case for a new sickle cell drug, eyeing a delayed FDA filing in ‘19

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Biotech VC firm outlines plans for $100M fund

Gilead's Kite uncouples from Fosun in China as Yescarta faces coverage obstacles

Breaking down silos with a new quantitative approach to drug development